Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Oncolytics
Autores principales: Qin, Haiying, Ramakrishna, Sneha, Nguyen, Sang, Fountaine, Thomas J., Ponduri, Anusha, Stetler-Stevenson, Maryalice, Yuan, Constance M., Haso, Waleed, Shern, Jack F., Shah, Nirali N., Fry, Terry J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300726/
https://ncbi.nlm.nih.gov/pubmed/30581986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2018.10.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares